U.S. Markets open in 4 hrs 57 mins

Zynex, Inc. (ZYXI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
13.87+0.45 (+3.35%)
At close: 1:00PM EST
Sign in to post a message.
  • P
    Pacha
    This is the reason why I bought it:
    Zynex Reports 83% Order Growth For July And August
    9:16 am ET September 3, 2020 (Benzinga) Print
    ENGLEWOOD, Colo., Sept. 3, 2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced order growth for July and August 2020.

    Aggregate orders in July and August were 83% above the prior year July and August aggregate and well above the 37% growth in the second quarter of 2020.

    Thomas Sandgaard, CEO of Zynex said: "In June, as many cities re-opened their doors for business, we have seen consistent order growth and it has continued in the third quarter as we posted 83% year-over-year order growth in July and August as we move closer to pre-COVID-19 sales rep productivity levels. We don't typically give order growth updates on a monthly basis but we thought it was important to share our progress as business returns to normal. Our continued order growth during this pandemic shows the strength of relationships our sales force has with many prescribers and the need for them to prescribe non-opioid, non-addictive prescription strength solutions for their patients in pain."

    The Company's full year 2020 revenue estimate is between $80 and $85 million whichis approximately 76% to 87% above last year's full year revenue of $45.5 million.

    2020 full year estimated adjusted EBITDA is $15.0 to $18.0 million.

    Our prescription-strength NexWave device is a healthy alternative to prescribing opioids as the first line of defense when treating pain. We continue to add additional sales reps in territories throughout the US that we have not covered previously.

    We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."
  • M
    Mike
    my question is why is kevin always on this form. I get you think it's a bad stock. but why are you always posting. you must have some of this stock
  • j
    javan
    Shorts are manipulating this stock and without them, the stock can reach its thru value instead of current fake prices. Put your shares for sale at some high price above $20 until cancel so short cannot take advantage of your shares. Most brokerages lend your shares to shorts to make a few dollars. Don't let brokerages and shorts take advantage of your shares. When you put your shares for sale at any price (very high price in this case) then brokerage cannot lend your shares.
  • M
    Maverick
    Great value stock and highly undervalued. Expect lots of upward momentum next weeks.
    Bullish
  • s
    steve
    Is the opioid issue less important than covid-19? Both dangerous and both are killing thousands monthly. If large companies are rushing to make a vaccine to save people's lives then Zynex is doing the same to prevent people to use opioids.
  • j
    javan
    So, what we got from Q3 earnings
    The most interesting thing is adding new products. Current products will grow and brings more revenue but the a medical device company has to invent new products constantly to have a real growth.
    I was happy to hear about blood monitoring CM-1500 that will flow with CM-1600 and CM-1700 with more functionalities and options. Even selling some to U.S. military in future. Yes, no rev from product yet but it will be plenty in future.
    In addition, pain management and rehabilitation are not done yet and as the company learns more, it will add more. There was a hint of acquisition that can be combined with current systems.
    Cash position is strong now with $41.2m compare to $14m last year.
    Order growth is above 120% compare to last year. Q4 rev is a humongous step-up that caused by order growth and more reps.
    Imagine if there was no Covid-19 or the Covid slows down next year after people get access to a vaccine. I think this company will explode upside since opioid epidemic costs thousand of lives monthly, probably worse than Covid-19.
  • s
    steve
    Future, Future...Growth, Growth. That's the way AMZN did it. Q3 is already in the past and Q4 in process with strong revenue, 30% growth quarter to quarter.
    In addition, the company has a strong cash position to acquire and create new technology and products while the revenue is ramping up.
    I see a jump from a small-cap company to a mid-cap company in a few years. Being a device company, it will be in demand significantly.
  • k
    kevin
    JIM, WOW! THANKS! I used your mention of seeking alpha to take a look at any thing they had to say about Zynex. Surprisingly an article from June pretty much covers what I've been saying about Zynex. I could have saved a lot of time typing posts about why this stock is a dog. Instead I could have just copied and pasted from the article :]
  • k
    kevin
    This stock is a great investment it could easily double in...OH! sorry my mistake, wrong board:]
  • k
    kevin
    You know, when I was carving the turkey yesterday some thing made me think of this stock :]
  • d
    david
    Here we go with creating a new division for the blood monitoring solution.
    I see Zynex as a large-cap company in the future. Time to catch this train now before it speeds up.
  • j
    joseph
    shorts will be destroyed soon, the CEO likes to pump the stock to the sky,so he can sell more shares at higher price . I expect some explosive news on the upcoming earning. The expectation has been priced in already, Now it just matter of news and guidance for next quarter
    Neutral
  • d
    david
    Qyarter **** Q2-2019 ** Q3-2019 ** Q4-Dec-2019 ** Q1-2020 ** Q2-2020 ** Q3-2020 ** Q4-2020
    Revenue **** 10.3M ***** 11.82M ****** 14.16M ****** 15.23M **** 19.26M *** 21.16M *** 25.85M

    Look at the above and the revenue growth Quarter/Quarter.
    This is the most amazing growth in the device medical field.
    The current reduction of rev for Q3 is not an issue since the company is still growing even in the pandemic situation. So what if growth is not that high and there is an obvious reason which is Covid-19. The fact is that there is growth even during the pandemic while other companies either lose revenue or worse go out of business.
  • L
    Lior
    Following the news Piper Sandler analyst Matt O’Brien reiterated his ZYXI buy rating and $30 price target (97% upside potential)

    https://finance.yahoo.com/news/zynex-tanks-23-demand-hit-063858743.html
    Bullish
  • j
    joseph
    The CEO owns nearly 50% of the shares, Kevin u really think he would let it tank? He will pump as much as possible before he sells all his shares
  • w
    wererabbit
    Dang, this is going to be a great buy soon. A bit oversold. Stock was higher back when their revenue was 20% lower.
  • a
    akram
    What's the matter today? Are shorts getting worried about ZYXI. They should be since this may zoom to $20 without any notice.
  • s
    steve
    I'm buying and averaging. I'm able to buy much more, at least 200k more shares. I have patience and I will see this baby over $30 by next year. It's a safe investment base on my DD and analysts' predictions.